Study summary

Acalabrutinib kept most people in response for more than 5 years

ACE-WM-001 trial, 5-year results · 106 people, phase 2 · Published July 2026, Blood Advances

94.6%response rate in relapsed disease

What was tested

Acalabrutinib, a daily BTK inhibitor pill, for treatment-naive and relapsed Waldenström macroglobulinemia.

What they found

What it means

Confirms that continuous BTK inhibitor treatment gives long-lasting control.

Blood Adv, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.